No attrition in research on wasting therapies.
Gilden
D
D
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy; D000273:Adipose Tissue; D045930:Anabolic Agents / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D013006:Growth Hormone / Q000627:therapeutic use; D019247:HIV Wasting Syndrome / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D009132:Muscles; D013792:Thalidomide / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism; D019562:Viral Load; D015430:Weight Gain
D045930:Anabolic Agents; D019380:Anti-HIV Agents; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide; D013006:Growth Hormone